November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

Global Study Tracks Adoption Rates of Long-Acting Antipsychotics in Schizophrenia Care

🧠 Mind & Mental Health 1 min read 👁 3

A meta-analysis involving more than 1.6 million participants found that 18.7 percent of individuals with schizophrenia receive long-acting injectable antipsychotics. Prescribing rates varied significantly by region, led by Europe at 26.0 percent compared to lower adoption in North America and Asia.

🧠Mind & Mental Health

Key points

  • A global review of over 1.6 million participants found an overall long-acting injectable antipsychotic utilization rate of 18.7 percent.
  • Adoption rates varied significantly by region, reaching 26.0 percent in Europe, 15.7 percent in North America, and 14.3 percent in Asia.
  • Researchers stressed that the pooled percentage reflects real-world practice differences rather than a universal standard of care.

Approximately 18.7 percent of individuals with schizophrenia receive long-acting injectable antipsychotics worldwide, according to a systematic review led by researchers Xiaobao Chen and Yubin Chen of Huzhou Normal University. The synthesis evaluated real-world prescription patterns across 26 observational studies encompassing 1,619,602 total participants and 258,382 users of long-acting injectables.

Geographic Differences in Clinical Practice

The analysis revealed notable differences in how these maintenance medications are prescribed across different regions. Clinical settings in Europe demonstrated the highest utilization rate at 26.0 percent. In comparison, prescription rates reached 15.7 percent in North America and 14.3 percent in Asia.

What to know: Long-acting injectable therapies are designed to assist with long-term treatment consistency in schizophrenia management. However, the researchers emphasized that the overall 18.7 percent pooled average reflects variations between healthcare settings rather than a established clinical target. Because the review evaluated observational data with high statistical heterogeneity, readers should view these findings as background trends and consult medical professionals for individualized treatment decisions.

Source Nature Health Sciences — nature.com/articles/s41398-026-04571-9 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.